January 2016 Global IP Report For Pharmaceuticals & Biotechnology

Continued investment in research and development is necessary to achieve and maintain a competitive advantage within the pharmaceuticals and biotechnology industries. Chief IP Counsel are charged with the protection of intellectual property that forms the foundation of an organization’s success within these areas, which is no small task. As such, this group of senior legal executives requires support from their C-suites, sufficient access to both in-house and outside resources, and a strategic roadmap for growth. This report presents the current landscape in which Chief IP Counsel within pharmaceuticals and biotechnology operate, and in what areas they are most focused for the year to come.

Report Structure And Methodology

This Global IP Data Report for Pharmaceuticals & Biotechnology was designed in conjunction with Consero’s invitation-only Intellectual Property Forums for Pharmaceuticals and Biotechnology in 2015. The 13-question report included responses from 48 Chief IP Counsel from Europe and North America, providing valuable insight into the areas of focus of this group of senior IP executives.

Download The Full Report


This Report In The Press

  • Corporate Counsel: Pharma’s IP Lawyers Getting Needed Attention
  • IP Frontline: Chief IP Counsel do not believe metrics provide useful measure of IP business value